Six years after its STAR Market IPO, Bio-Thera Solutions,Ltd. (688177.SH) remains trapped in a cycle of mounting losses tied to escalating research and development spending. Based on its first-half 2026 performance forecast, the company expects a net loss attributable to shareholders between 230 million and 290 million yuan, representing a year-on-year increase of up to 165 million yuan. Since its 2020 listing, the company has only achieved a brief profit in 2021, accumulating total losses of 2.15 billion yuan to date. This divergence between rising revenue and persistent losses stems from a structural imbalance where R&D spending growth significantly outpaces revenue growth. For the first half of the year, revenue is projected to increase by 13.58% to 20.37%, while R&D expenses are expected to surge by 28.67% to 40.14%. As key pipeline candidates BAT8006 and BAT3306 enter critical clinical trial phases, high costs for contract research organizations and patient enrollment continue to drive up short-term expenses. More critically, the filing date for the core drug BAT3306 has been pushed back from July 2027 to 2028, further extending the timeline for commercialization and raising doubts about the market's tolerance for the company's strategy of trading losses for pipeline development.

Debt Structure Holds Hidden Risks, Cash Flow Relies on Three Pillars

As of the end of 2025, the company's debt-to-asset ratio stood at 83.56%, with cash and cash equivalents totaling only 219 million yuan against 312 million yuan in short-term interest-bearing debt, leaving a short-term funding gap of approximately 130 million yuan. However, a deeper look at the liability structure reveals that nearly 64% of total liabilities are operational. Contract liabilities and other non-current liabilities amount to 855 million yuan, primarily consisting of advance payments from overseas partners for licensing rights. These non-cash liabilities do not represent immediate repayment obligations. After excluding these factors, the company's actual debt-to-asset ratio drops to 46.18%, below the industry average. Still, this does not guarantee safety. The company's financial stability is heavily tied to the approval and commercialization timeline of its overseas pipeline. Any adjustments to partner orders or delays in clinical progress would slow revenue recognition and rapidly weaken its ability to generate cash flow. Fortunately, the company has three support mechanisms for liquidity: the remaining 270 million yuan in milestone payments from the sale of the Betanin rights (total consideration of 450 million yuan) is expected in the second half of the year; unused bank credit lines exceed 600 million yuan; and advance payments from partners like Hikma will be gradually recognized as revenue as milestones are met. However, if core pipeline clinical data or overseas regulatory approvals face adverse developments, the reliability of these three safety nets remains highly uncertain.

Commercialization Base Faces Pressure, Self-Sustaining Cash Flow Far From Established

Looking at the performance of its marketed products, Bio-Thera Solutions,Ltd.'s commercial foundation remains fragile. The flagship product, adalimumab (Golimumab), generated 560 million yuan in sales in 2025, a 32.69% increase, making it the primary source of revenue. However, sales of tocilizumab (Shirui) plummeted by 52.57% year-on-year due to inventory digestion by overseas partner Organon, which has paused new orders, highlighting the risk of dependence on a single customer. Meanwhile, bevacizumab's supply, under a licensing agreement, faces declining prices, resulting in a negative gross margin of -17.33% on reported supply costs. Although the overall gross margin reaches 33% after including sales commissions, the quality of earnings is clearly low. More concerning is the uncertainty surrounding the timeline for the transfer of core asset rights. While Betanin has been sold to Lepu Medical, the remaining 270 million yuan payment is contingent on the full approval of the drug marketing authorization holder transfer and production transfer. Any delays in these approvals would directly impact the company's profit for the year. Under the combined pressures of sustained high R&D spending, delays in core pipeline launches, and fluctuating overseas demand for certain products, the most critical question for management is whether Bio-Thera Solutions,Ltd. can successfully navigate the cycle from R&D to commercialization to self-sustaining cash flow before its cash reserves are exhausted.